Share on LinkedInShare on LinkedIn

ARTICLE · 24 NOVEMBER 2021

Current Patenting Issues In Europe Facing Life Sciences/Biotech Innovators And Effective Claim Drafting Strategies To Avoid Pitfalls

J A Kemp
J A Kemp
Contributor
J A Kemp

J A Kemp

J A Kemp is one of the largest European patent and trade mark attorney firms, with offices in...

View firm profile
Explore more from J A Kemp

This paper was originally submitted to the American Intellectual Property Law Association (AIPLA) ahead of its 2021 Annual Meeting and was the subject of a presentation at a plenary session there on 28 October 2021.

United KingdomIntellectual Property

This paper was originally submitted to the American Intellectual Property Law Association (AIPLA) ahead of its 2021 Annual Meeting and was the subject of a presentation at a plenary session there on 28 October 2021. The author, Andrew Bentham, is a partner in the Biotechnology and Life Sciences group of J A Kemp LLP (Cambridge, UK).

This paper is in two sections. The first relates to current topics, issues and developments in European patent practice in that may be relevant for innovators in the life sciences. As far as possible, this first part tracks the issues discussed from a US perspective in the paper submitted by my co-panellist Courtenay Brinckerhoff of Foley & Lardner LLP, in the hope that US-based readers can better compare the situation in the US with that in Europe. The second part, focussing on differences between US and European practice and how to avoid these differences becoming pitfalls for US applicants, is more timeless - as in general

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from